Table 2 Clinical, serological, pathological, and bacteriological parameters in treated animals
Study Site | Kenya (VSRI) | Zambia (CVRI) | ||||||
|---|---|---|---|---|---|---|---|---|
Treatment | Saline | Tulathromycin | Gamithromycin | Oxytetracycline | Saline | Tulathromycin | Gamithromycin | Oxytetracycline |
Number of Cattle | 15 (14*) | 15 | 15 | 15 | 13 | 13 | 13 | 14 |
Max. number of pyrexia days | 2 | 1 | 1 | 0 | 6 | 1 | 1 | 1 |
Number euthanased | 6 | 0 | 1 | 1 | 3 | 0 | 0 | 0 |
Max. CFT titer | 640 b | 320 | 320 | 80 | 2560 | 20 | 640 | 640 |
Number with acute/subacute or chronic lesions | 14 | 3 | 4 | 1 | 12 | 0 | 0 | 3 |
Number (%) with Mycoplasma isolated from tissue, pleural fluid or BAL | 5/14 (36%) | 0 | 2/15 (13%) | 1/15 (7%) | 10/13 (77%) | 1/13 (8%) | 2/13 (15%) | 6/14 (43%) |
Number (%) with Mycoplasma isolated from nasal swabs | 3/15 (20%) | 1/15 (7%) | 4/15 (27%) | 3/15 (20%) | 2/13 (15%) | 0 | 2/13 (15%) | 2/14 (14%) |
Average HT lesion score (s.d.) a | 3.40 (2.03) | 0.33 (0.72) | 0.67 (1.18) | 0.40 (1.55) | 2.54 (1.90) | 0 | 0 | 0.57 (1.22) |
p-value for significance (lesion scores) | Groups (overall): p ≤ 0.001; s.e. 0.375 | Groups (overall): p = 0.003; s.e. 0.438 (n = 13); 0.423 (n = 14) | ||||||
Comparison | Group 1 vs. | Group 2 p ≤ 0.001 | Group 3 p ≤ 0.001 | Group 4 p ≤ 0.001 | Group 1 vs. | Group 2# (p ≤ 0.001) | Group 3# (p ≤ 0.001) | Group 4 p ≤ 0.003 |